BRD2 and cancer: We describe: 1) notable differences between Brd2 heterozygous and wildtype mice in aging-related phenotypes, including cancer incidence, kidney function, lifespan, and other aging-related measures, and, 2) evidence supporting the hypothesis that Brd2-haploinsufficiency increases lifespan and healthspan, in part, through the upregulation of cytoprotective genes.